Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
September 06 2018 - 4:20PM
Business Wire
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical
company, announced that on September 5, 2018 the Compensation
Committee of Puma’s Board of Directors approved the grant of
inducement restricted stock unit awards covering an aggregate of
31,125 shares of Puma common stock to four new non-executive
employees.
The awards were granted under Puma’s 2017 Employment Inducement
Incentive Award Plan, which was adopted on April 27, 2017 and
provides for the granting of equity awards to new employees of
Puma. The restricted stock unit awards vest over a three-year
period, with one-third of the shares underlying each award vesting
on the first anniversary of the award’s vesting commencement date
(August 1, 2018 for two of the awards and September 1, 2018 for the
other two awards) and one-sixth of the shares underlying each award
vesting on each six-month anniversary of the vesting commencement
date thereafter, subject to continued service. The awards were
granted as an inducement material to the new employees entering
into employment with Puma, in accordance with Nasdaq Listing Rule
5635(c)(4).
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a
focus on the development and commercialization of innovative
products to enhance cancer care. The Company in-licenses the global
development and commercialization rights to three drug candidates —
PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.
Neratinib, oral was approved by the U.S. Food and Drug
Administration in July 2017 for the extended adjuvant treatment of
adult patients with early stage HER2-overexpressed/amplified breast
cancer, following adjuvant trastuzumab-based therapy, and is
marketed in the United States as NERLYNX® (neratinib) tablets.
NERLYNX was granted marketing authorization by the European
Commission for the extended adjuvant treatment of hormone
receptor-positive HER2-positive early stage breast cancer in
September 2018. NERLYNX is a registered trademark of Puma
Biotechnology, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180906005777/en/
Puma Biotechnology, Inc.Alan H. Auerbach or Mariann Ohanesian,
+1 424 248
6500info@pumabiotechnology.comir@pumabiotechnology.comorRusso
PartnersDavid Schull or Amiad Finkelthal, +1 212 845
4200david.schull@russopartnersllc.comamiad.finkelthal@russopartnersllc.com
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Sep 2023 to Sep 2024